SPRINT研究中利钠肽水平变化与后续肾功能下降的关联
SPRINT前瞻性观察研究纳入8005例有基线和1年NT-proBNP测量的参与者,分析1年NT-proBNP变化与后续eGFR年化变化及eGFR下降≥30%的关联。结果显示NT-proBNP降低≥25%与eGFR下降较慢相关,升高≥25%与eGFR下降较快及eGFR下降≥30%风险增加相关,尤其在CKD患者中。
要点
- 在SPRINT参与者中,1年NT-proBNP降低≥25%与后续eGFR下降较慢独立相关。
- 1年NT-proBNP升高≥25%与CKD患者eGFR下降较快及eGFR下降≥30%风险增加相关。
- NT-proBNP变化与肾功能下降的关联在CKD患者中比无CKD者更强。
核心结论
- 血压治疗期间NT-proBNP的变化与后续肾功能下降独立相关,尤其在CKD患者中。
研究设计与样本
- 前瞻性观察研究,纳入8005例SPRINT参与者,均有基线和1年NT-proBNP测量。
主要发现
- 与1年NT-proBNP稳定相比,NT-proBNP降低≥25%与CKD患者eGFR下降较慢相关(校正差值1.09%/年;95%CI 0.35-1.83),与无CKD患者也相关(校正差值0.51%/年;95%CI 0.21-0.81;交互作用P=0.4)。
- 在CKD患者中,NT-proBNP升高≥25%与eGFR下降较快相关(校正差值-1.04%/年;95%CI -1.72至-0.36),并与eGFR下降≥30%风险相关(校正OR 1.44;95%CI 1.06-1.96);这些关联在CKD患者中比无CKD者更强(交互作用P=0.01和P<0.001)。
- 无论SPRINT随机血压分组如何,关联相似(交互作用P>0.2)。
临床怎么用
- 未来研究应评估常规NT-proBNP测量是否可用于监测高血压治疗期间的肾脏风险。
局限性
- 排除了糖尿病患者和蛋白尿>1 g/d者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Novel approaches to the assessment of kidney disease risk during hypertension treatment are needed because of the uncertainty of how intensive blood pressure (BP) lowering impacts kidney outcomes. We determined whether longitudinal N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements during hypertension treatment are associated with kidney function decline. STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 8,005 SPRINT (Systolic Blood Pressure Intervention Trial) participants with NT-proBNP measurements at baseline and 1 year. EXPOSURE: 1-year change in NT-proBNP categorized as a ≥25% decrease, ≥25% increase, or <25% change (stable). OUTCOME: Annualized change in estimated glomerular filtration rate (eGFR) and ≥30% decrease in eGFR. ANALYTICAL APPROACH: Linear mixed-effect and logistic regression models were used to evaluate the association of changes in NT-proBNP with subsequent annualized change in eGFR and ≥30% decrease in eGFR, respectively. Analyses were stratified by baseline chronic kidney disease (CKD) status. RESULTS: Compared with stable 1-year NT-proBNP levels, a ≥25% decrease in NT-proBNP was associated with a slower decrease in eGFR in participants with CKD (adjusted difference, 1.09%/y; 95% CI, 0.35-1.83) and without CKD (adjusted difference, 0.51%/y; 95% CI, 0.21-0.81; P = 0.4 for interaction). Meanwhile, a ≥25% increase in NT-proBNP in participants with CKD was associated with a faster decrease in eGFR (adjusted difference, -1.04%/y; 95% CI, -1.72 to -0.36) and risk of a ≥30% decrease in eGFR (adjusted odds ratio, 1.44; 95% CI, 1.06-1.96); associations were stronger in participants with CKD than in participants without CKD (P = 0.01 and P < 0.001 for interaction, respectively). Relationships were similar irrespective of the randomized BP arm in SPRINT (P > 0.2 for interactions). LIMITATIONS: Persons with diabetes and proteinuria >1 g/d were excluded. CONCLUSIONS: Changes in NT-proBNP during BP treatment are independently associated with subsequent kidney function decline, particularly in people with CKD. Future studies should assess whether routine NT-proBNP measurements may be useful in monitoring kidney risk during hypertension treatment. PLAIN-LANGUAGE SUMMARY: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker in the blood that reflects mechanical stress on the heart. Measuring NT-proBNP may be helpful in assessing the risk of long-term losses of kidney function. In this study, we investigated the association of changes in NT-proBNP with subsequent kidney function among individuals with and without chronic kidney disease. We found that increases in NT-proBNP are associated with a faster rate of decline of kidney function, independent of baseline kidney measures. The associations were more pronounced in individuals with chronic kidney disease. Our results advance the notion of considering NT-proBNP as a dynamic tool for assessing kidney disease risk.
引用
- Ascher SB, Berry JD, Katz R, et al. Changes in Natriuretic Peptide Levels and Subsequent Kidney Function Decline in SPRINT. Am J Kidney Dis. 2023. PMID: 37992982. doi:10.1053/j.ajkd.2023.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。